Browse > Article
http://dx.doi.org/10.4489/MYCO.2008.36.2.102

Production of the Acetylcholinesterase Inhibitor from Yarrowia lipolytica S-3  

Lee, Dae-Hyung (Department of Life Science and Genetic Engineering, Paichai University)
Lee, Ji-Su (Department of Life Science and Genetic Engineering, Paichai University)
Yi, Sung-Hun (Korea Food Research Institute)
Lee, Jong-Soo (Department of Life Science and Genetic Engineering, Paichai University)
Publication Information
Mycobiology / v.36, no.2, 2008 , pp. 102-105 More about this Journal
Abstract
The acetylcholinesterase (AChE) inhibitor of Yarrowia lipolytica S-3 was maximally produced when it was incubated at $30^{\circ}C$ for 36 h in an optimal medium containing 1% yeast extract, 2% peptone and 2% glucose, with an initial pH 6.0. The final AChE inhibitory activity under these conditions was an $IC_{50}$ value of 64mg/ml. After partial purification of the AChE inhibitor by means of systematic solvent extraction, the final $IC_{50}$ value of the partially purified AChE inhibitor was 0.75 mg/ml. We prepared a test product by using the partially purified AChE inhibitor and then determined its stability for the development of a new antidementia commercial product. The test product was stable at room temperature for 15 weeks.
Keywords
Acetylcholinesterase inhibitor; Antidementia; Yarrowia lipolytica S-3;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Lee, D. H., Lee, D. H. and Lee, J. S. 2007. Characterization of a new antidementia $\beta$-secretase inhibitory peptide from Saccharomyces cerevisiae. J. Enzmictec. 42:83-88.
2 Kim, J. H., Lee, D. H., Jeong, S. C., Chung, K. S. and Lee, J. S. 2004. Characterization of antihypertensive angiotensin Io-converting enzyme inhibitor from Saccharomyces cerevisiae. J. Microbiol. Biotechnol. 14:1318-1323
3 Lahiri, D. K., Farlow, M. R., Greig, N. H. and Sambamurti, K. 2002. Current drug targets for Alzheimer's disease treatment. Drug Devel. Res. 56:267-281   DOI   ScienceOn
4 Alzheimer, A. 1907. Ueber eine eigenartige Erkrankung der Hirnrinde. Allgem. Zeit. Psychiatrie Psychisch-Gerichtliche Med. 64:146-148
5 Davis, K. L., Mohs, R. C., Marin, D., Purohit, D. P., Perl, D. P., Lantz, M., Austin, G. and Haroutunian, V. 1999. Cholinergic markers in elderly patients with early signs of Alzheimer's disease. J. Amer. Med. Association. 281:1401-1406   DOI   ScienceOn
6 Rossor, M. N., Enson, P. C., Nountjoy, C. Q., Roth, M. and Iversen, L. L. 1980. Reduce anounts of immunoreactive sornatostatin in the temporal cortex in senile dementia of Alzheimer type. Neurosci. Lett. 373-377
7 Lee, D. H. 2007. Production of a anti-dementia acetylcholinesterase (AChE) inhibitor from Yeast. Master Thesis. Paichai Uni.Dept. of Life Sci. and Genetic Eng. Korea
8 Ellman, G. L., Courtney, K. D., Andres, V. and Featherstone, R. M. 1961. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 7:68-75
9 Hasselmo, M. E. 1995. Neuromodulation and cortical function: Modeling the physiological basis of behavior. Behav. Brain Res. 67:1-27   DOI   ScienceOn
10 Eubanks, L. M., Rogers, C. J., Beuscher, A. E. 4th, Koob, G. F., Olson, A. J., Dickerson, T. J. and Janda, K. D. 2006. A molecular link between the active component of marijuana and Alzheimer's disease pathology. Mol. Pharm. 3:773-777   DOI   ScienceOn
11 Rossor, M. N. 1982. Dementia. Lancet 320:1200-1204.   DOI   ScienceOn
12 Yu, A. J. and Dayan, P. 2005. Uncertainty, neuro-modulation and attention. Neuron 46:681-692   DOI   ScienceOn